Adcytherix SAS
Adcytherix is a biopharmaceutical company based in Marseille, France, focused on developing novel antibody drug conjugates (ADCs) to treat high unmet need diseases such as cancer. Led by a seasoned management team and supported by leading life science investors, the company aims to establish itself as a leading ADC developer to address urgent patient needs.
Industries
Nr. of Employees
small (1-50)
Adcytherix SAS
17 boulevard Augustin Cieussa, 13007 Marseille, France
Products
Preclinical antibody-drug conjugate programs
Proprietary ADC development programs in early-stage (preclinical) development; specific product details not published.
Preclinical antibody-drug conjugate programs
Proprietary ADC development programs in early-stage (preclinical) development; specific product details not published.
Services
End-to-end discovery and preclinical development services for antibody-drug conjugate programs, from target discovery through candidate selection and preclinical proof-of-concept.
End-to-end discovery and preclinical development services for antibody-drug conjugate programs, from target discovery through candidate selection and preclinical proof-of-concept.
Expertise Areas
- Antibody-drug conjugate development
- Preclinical development
- CMC and biologics manufacturing strategy
- Clinical development for oncology
Key Technologies
- Antibody-drug conjugate platforms
- Conjugation/linker chemistry
- Preclinical in vitro and in vivo models
- Biologics process development
News & Updates
Adcytherix announced its incorporation and seed funding of € 30 million to develop novel ADCs for high unmet need diseases such as cancer. The company was founded by Jack Elands, Xavier Preville, and Carsten Dehning, with seed funding led by Pontifax and supported by other top-tier investors.
Adcytherix announced its incorporation and seed funding of € 30 million to develop novel ADCs for high unmet need diseases such as cancer. The company was founded by Jack Elands, Xavier Preville, and Carsten Dehning, with seed funding led by Pontifax and supported by other top-tier investors.